Done. Is CD37-targeted therapy a viable alternative in the treatment of diffuse large B-cell lymphoma? - Debiopharm
Home Drug development Publications Is CD37-targeted therapy a via…

Is CD37-targeted therapy a viable alternative in the treatment of diffuse large B-cell lymphoma? Interviews with two key opinion leaders

Grzegorz S. Nowakowski1, Wojciech Jurczak2

EMJ. 2021;6[1]:33-39

1Mayo Clinic, Rochester, Minnesota, USA
2Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland